Late onset azotemia from RAAS blockade in CKD patients with normal renal arteries and no precipitating risk factors

Renal Failure

Volumn 30, Issue 1, 2008, Pages 73-80

  Onuigbo, Macaulay A C ^a,b   Onuigbo, Nnonyelum T C ^c  

^a Mayo Clinic   (United States)

^b Mayo Health System   (United States)

^c NT Systems   (United States)

Author keywords

Chronic kidney disease; ESRD; Hypertension; Microvascular renal artery stenosis (mRAS); RAAS blockade

Indexed keywords

CANDESARTAN;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CONVENTIONAL ANGIOGRAPHY; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; KIDNEY ARTERY STENOSIS; KIDNEY CIRCULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; UREMIA;

ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AZOTEMIA; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MICROCIRCULATION; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; RENAL ARTERY; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 38149108349     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220701742161     Document Type: Article

References (45)

1. Onuigbo M, Weir MR. Evidence-based treatment of hypertension in patients with diabetes mellitus. Diabetes Obes Metab. 2003;5(1):13-26.
2. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med. 1992;327(10):685-691; Erratum: N Engl J Med. 1992;327(24):1768.
3. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329(20):1456-1462; Erratum: N Engl J Med. 1993; 330(2):152.
4. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354(9176):359-364.
5. Packer M, Poole-Wilson PA, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100(23):2312-2318.
6. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717.
7. Mogensen CE, Neldam S, Tikkanen I, et al. Randomized controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: The Candesartan And Lisinopril Microalbuminuria (CALM) study. BMJ 2000;321(7274):1440-1444.
8. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomized trial - the Losartan Heart Failure Survival Study ELITE II. Lancet. 2000;355(9215):1582-1587.
9. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355(9200):253-259. Erratum: Lancet. 2000; 356(9232):860.
10. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
11. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
12. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
13. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003;349(20):1893-1906.
14. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-overall programme. Lancet. 2003;362(9386):759-766.
15. Pitt B, Remme W, Zannad F, et al., for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
16. Manolio TA, Cutler JA, Furberg C, et al. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995;155(8):829-837.
17. Carter BL, Malone DC, Ellis SL, et al. Antihypertensive drug utilization in hypertensive veterans with complex medication profiles. J Clin Hypertens (Greenwich). 2000;2(3):172-180.
18. Nelson CR, Knapp DA. Trends in antihypertensive drug therapy of ambulatory patients by U.S. office-based physicians. Hypertension. 2000;36(4):600-603.
19. Scarsi KK, Bjornson DC. The use of ACE inhibitors as renoprotective agents in Medicaid patients with diabetes. Ann Pharmacother. 2000;34(9):1002-1006.
20. Hsu CY, Vittinghoff E, Lin F, et al. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann Intern Med. 2004;141(2):95-101.
21. Szczech LA, Lazar IL. Projecting the United States ESRD population: Issues regarding treatment of patients with ESRD. Kidney Int Suppl. 2004; 90:S3-S7.
22. Jones CA, Krolewski AS, Rogus J, et al. Epidemic of endstage renal disease in people with diabetes in the United States population: Do we know the cause? Kidney Int. 2005;67(5):1684-1691.
23. Suissa S, Hutchinson T, Brophy JM, et al. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int. 2006;69:913-919.
24. Silas JH, Klenka Z, Solomon SA. Captopril induced reversible renal failure: A marker of renal artery stenosis affecting a solitary kidney. Br Med J (Clin Res Ed). 1983;286(6379):1702-1703.
25. Murphy BF, Whitworth JA, Kincaid-Smith P. Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics. Br Med J (Clin Res Ed). 1984;288(6420):844-845.
26. Jackson B, McGrath BP, Matthews PG, et al. Differential renal function during angiotensin converting enzyme inhibition in renovascular hypertension. Hypertension. 1986;8:650-654.
27. Kalra PA, Mamtora H, Holmes AM, et al. Renovascular disease and renal complications of angiotensin-converting enzyme inhibitor therapy. Q J Med. 1990;7(282):1013-1018.
28. Devoy MAB, Tomson CR, Edmunds ME, et al. Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible. J Intern Med. 1992;232(6):493-498.
29. Thomas MC. Diuretics, ACE inhibitors and NSAIDs - the triple whammy. Med J Aust. 2000;172(4):184-185.
30. Boyd IW, Mathew TH, Thomas MC. Cox-2 inhibitors and renal failure: The triple whammy revisited. Med J Aust. 2000;173:274.
31. Descombes E, Fellay G. End-stage renal failure after irbesartan prescription in a diabetic patient with previously stable chronic renal insufficiency. Ren Fail. 2000;22(6):815-821.
32. Vachharajani TJ, Dacie JE, Yaqoob MM, et al. Detection of occult renovascular disease in unexplained chronic kidney disease. Int Urol Nephrol. 2005;37(4):793-796.
33. Schalekamp MADH, Wenting GJ. Angiotensin converting enzyme inhibition in renovascular hypertension: Failure of the stenotic kidney. Lancet. 1984;1(8374):464.
34. Hricik DE, Browning PJ, Kopelman R, et al. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenosis or renal-artery stenosis in a solitary kidney. N Eng J Med. 1983;308(7):373-376.
35. Wenting GJ, Tan-Tjiong HL, Derkx FH, et al. Split renal function after captopril in unilateral renal artery stenosis. Br Med J (Clin Res Ed). 1984:288(6421):886-890.
36. Jackson B, Matthews PG, McGrath BP, et al. Angiotensin converting enzyme inhibition in renovascular hypertension: Frequency of reversible renal failure. Lancet. 1984;1(8370):225-226.
37. Hollenberg NK. Angiotenisn-converting enzyme inhibition: Renal aspects. J Cardiovasc Pharmacol. 1985;7:S40-S44.
38. Hansen HP, Rossing P, Tarnow L, et al. Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int. 1995;47(6):1726-1731.
39. Apperloo AJ, de Zeeuw D, de Jong PE. A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Ann Intern Med. 1997;51(3):793-797.
40. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-470.
41. Onuigbo MAC, Onuigbo NT. Late onset renal failure from angiotensin blockade (LORFFAB): A prospective thirtymonth Mayo Health system Clinic experience. Med Sci Monit. 2005;11(10):CR462-CR469.
42. Onuigbo MAC, Onuigbo NTC. Late-onset renal failure from RAAS blockade. Kidney Int. 2006;70:1378-1379.
43. Raine AE. Angiotensin-converting enzyme inhibition and renovascular disease. Q J Med. 1990;77(282):997-999.
44. Ballermann BJ, Onuigbo MAC. Angiotensins. In: Frsy, JCS, ed. Handbook of Physiology. Section 7, The Endocrine System, Vol III. Endocrine Regulation of water and Electrolyte Balance. New York: Oxford University Press; 2000,pp. 104-155.
45. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? Arch Intern Med. 2000;160(5):685-693.